Astra Zeneca
AstraZeneca PLC, a leading global biopharmaceutical company, is headquartered in Cambridge, GB. Founded in 1999 through the merger of Astra AB and Zeneca Group PLC, the company has established a strong presence in key operational regions, including North America, Europe, and Asia. Specialising in the research, development, and manufacturing of innovative medicines, AstraZeneca focuses on areas such as oncology, cardiovascular, renal, and respiratory diseases. With a commitment to advancing healthcare, AstraZeneca is renowned for its unique portfolio of products, including groundbreaking therapies like Tagrisso and Imfinzi. The company has achieved significant milestones, including rapid vaccine development during the COVID-19 pandemic, solidifying its position as a market leader in the pharmaceutical industry. AstraZeneca continues to drive innovation, aiming to improve patient outcomes worldwide.
DitchCarbon Score
How does Astra Zeneca's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Astra Zeneca's score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Astra Zeneca's reported carbon emissions
In 2024, AstraZeneca reported total greenhouse gas emissions of approximately 6,000,000,000 kg CO2e, with significant contributions from Scope 1, Scope 2, and Scope 3 emissions. Specifically, Scope 1 emissions were about 125,386,000 kg CO2e, while Scope 2 emissions totalled approximately 14,210,000 kg CO2e (market-based) and 217,026,000 kg CO2e (location-based). The majority of emissions stemmed from Scope 3, which accounted for about 5,897,822,000 kg CO2e. AstraZeneca has set ambitious climate commitments, aiming for a 98% reduction in absolute Scope 1 and 2 GHG emissions by 2026, using 2015 as the baseline year. Additionally, the company targets a 50% reduction in absolute Scope 3 emissions by 2030, with specific goals to cut emissions from fuel and energy-related activities, upstream and downstream leased assets, and the use of sold products by up to 95% by 2030. The company is also committed to achieving 100% renewable electricity consumption globally by 2025 and transitioning to a fully electric road fleet by the end of 2025. Furthermore, AstraZeneca aims to become carbon negative across its value chain by 2030 and has pledged to reach net-zero greenhouse gas emissions by 2045. These initiatives reflect AstraZeneca's commitment to sustainability and its alignment with science-based targets, reinforcing its role as a leader in the pharmaceutical industry in addressing climate change.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 298,498,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 322,319,000 | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Astra Zeneca is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
